Evaluation of the role of the GPIb-IX-V receptor complex in development of the platelet storage lesion

Vox Sanguinis

Volumn 111, Issue 3, 2016, Pages 247-256

  Rijkers, M ^a   van der Meer, P F ^b   Bontekoe, I J ^b   Daal, B B ^b   de Korte, D ^a,b   Leebeek, F W G ^c   Voorberg, J ^a   Jansen, A J G ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

aggregation; glycoprotein Ib ; mirasol; platelet storage lesion; sialic acid

Indexed keywords

GLYCAN DERIVATIVE; PADGEM PROTEIN; PLATELET GLYCOPROTEIN GPIB IX V COMPLEX; RECOMBINANT VON WILLEBRAND FACTOR; SIALIC ACID; THROMBIN RECEPTOR; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG; CRYOPROTECTIVE AGENT; GLYCOPROTEIN RECEPTOR GPIB-IX; N ACETYLNEURAMINIC ACID; PROTEIN BINDING; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; PLATELET STORAGE LESION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SIALYLATION; SURFACE PROPERTY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTE PRESERVATION; BLOOD STORAGE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; THROMBOCYTE;

BLOOD PLATELETS; BLOOD PRESERVATION; CRYOPROTECTIVE AGENTS; FLOW CYTOMETRY; HUMANS; N-ACETYLNEURAMINIC ACID; P-SELECTIN; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; RISTOCETIN; VON WILLEBRAND FACTOR;

EID: 84969988889     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12416     Document Type: Article

References (34)

1. Capocelli KE, Dumont LJ: Novel platelet storage conditions: additive solutions, gas, and cold. Curr Opin Hematol 2014; 21:491–496
2. Shrivastava M: The platelet storage lesion. Transfus Apher Sci Elsevier Ltd 2009; 41:105–113
3. Holme S: Storage and quality assessment of platelets. Vox Sang 1998; 2:207–216
4. Canault M, Duerschmied D, Brill A, et al.: p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood 2010; 115:1835–1842
5. Jaremo P, Rubach-Dahlberg E, Solum NO: Correlations of light transmission changes to changes of platelet glycoprotein Ib during storage of platelet concentrates. Thromb Res 1993; 69:467–477
6. Andrews RK, Shen Y, Gardiner EE, et al.: The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82:357–364
7. Andrews RK, Karunakaran D, Gardiner EE, et al.: Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol 2007; 27:1511–1520
8. Ozaki Y, Asazuma N, Suzuki-Inoue K, et al.: Platelet GPIb-IX-V-dependent signaling. J Thromb Haemost 2005; 3:1745–1751
9. Jansen AJG, Josefsson EC, Rumjantseva V, et al.: Desialylation accelerates platelet clearance after refrigeration and initiates GPIbα metalloproteinase-mediated cleavage in mice. Blood 2012; 119:1263–1273
10. Grozovsky R, Begonja AJ, Liu K, et al.: The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2014; 21:47–54
11. Ruane PH, Edrich R, Gampp D, et al.: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44:877–885
12. van der Meer PF, Bontekoe IJ, Daal BB, et al.: Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? Transfusion 2015; 55:1900–1908
13. Ashford P, Gulliksson H, Georgsen J, et al.: Standard terminology for platelet additive solutions. Vox Sang 2010; 98:577–578
14. Holme S, Moroff G, Murphy S: A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Transfusion 1998; 38:31–40
15. VandenBroeke T, Dumont LJ, Hunter S, et al.: Platelet storage solution effects on the accuracy of laboratory tests for platelet function: a multi-laboratory study. Vox Sang 2004; 86:183–188
16. Verhoeven AJ, Verhaar R, Gouwerok EGW, et al.: The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005; 45:82–89
17. van den Biggelaar M, Bierings R, Storm G, et al.: Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies. J Thromb Haemost 2007; 5:2235–2242
18. Stel HV, Sakasiassen KD, Scholte BJ, et al.: Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood 1984; 63:1408–1415
19. Thiagarajan P, Tait JF: Binding of annexin V/placental anticoagulant protein I to platelets. J Biol Chem 1990; 265:17420–17423
20. Metcalfe P, Williamson LM, Reutelingsperger CP, et al.: Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997; 98:86–95
21. Hoffmeister KM: The role of lectins and glycans in platelet clearance. J Thromb Haemost 2011; 9:35–43
22. Rumjantseva V, Grewal PK, Wandall HH, et al.: Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009; 15:1273–1280
23. Skripchenko A, Thompson-Montgomery D, Awatefe H, et al.: Addition of sialidase or p38 MAPK inhibitors does not ameliorate decrements in platelet in vitro storage properties caused by 4 & storage. Vox Sang 2014; 107:1–8
24. Koerner TAW, Weinfeld HM, Yu RK, et al.: The effect of storage on the ganglioside content of human platelets. Transfusion 1986; 26:77–81
25. Molin K, Fredman P, Svennerholm L: Binding specificities of the lectins PNA, WGA and UEA I to polyvinylchloride-adsorbed glycosphingolipids. FEBS Lett 1986; 205:51–55
26. Kostelijk E, Folman C, Gouwerok C, et al.: Increase in glycocalicin levels in platelet concentrates stored in plasma or synthetic medium for 8 days: comparison with other platelet activation markers. Vox Sang 2000; 79:21–26
27. Keuren JFW, Cauwenberghs S, Heeremans J, et al.: Platelet ADP response deteriorates in synthetic storage media. Transfusion 2006; 46:204–212
28. Hardy AR, Conley PB, Luo J, et al.: P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 2005; 105:3552–3560
29. Zeddies S, De Cuyper IM, Van Der Meer PF, et al.: Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54:2292–2300
30. Abonnenc M, Sonego G, Crettaz D, et al.: In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion 2015; 55:2219–2230
31. Perez-Pujol S, Tonda R, Lozano M, et al.: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45:911–919
32. Schubert P, Coupland D, Culibrk B, et al.: Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013; 53:3164–3173
33. Johnson L, Marks D: Treatment of platelet concentrates with the mirasol pathogen inactivation system modulates platelet oxidative stress and NF-κB activation. Transfus Med Hemother 2015; 42:167–173
34. The Group Mirasol Clinical Evaluation Study: A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50:2362–2375